Table 2

Risk of ovarian cancer in association with analgesic use—RPCI, Buffalo, NY 1982–1996

Cases n (%)Controls n (%)Crude OR (95% CI)Adjusted ORa (95% CI)
Aspirin use
Nonuser480 (87.8)959 (87.7)1.01.0
Regular userb67 (12.2)135 (12.3)0.99 (0.73–1.36)1.0 (0.73–1.39)
1–6 tablets/wk37 (6.8)70 (6.4)1.05 (0.70–1.80)1.14 (0.74–1.74)
7+ tablets/wk30 (5.5)65 (5.9)0.92 (0.59–1.44)0.87 (0.54–1.39)
0.5–10 yr of use22 (4.0)33 (3.0)1.33 (0.77–2.31)1.32 (0.75–2.34)
11+ yr of use45 (8.2)102 (9.3)0.88 (0.61–1.27)0.90 (0.61–1.32)
Acetaminophen use
Nonuser518 (94.7)996 (91.0)1.01.0
Regular userb29 (5.3)98 (9.0)0.57 (0.37–0.87)0.56 (0.34–0.86)
1–6 tablets/wk26 (4.8)78 (7.1)0.64 (0.41–1.01)0.62 (0.37–0.98)
7+ tablets/wk3 (0.5)19 (1.7)0.30 (0.09–1.03)0.32 (0.09–1.08)
0.5–10 yr of use16 (2.9)51 (4.7)0.60 (0.34–1.07)0.60 (0.34–1.07)
11+ yr of use13 (2.4)47 (4.3)0.53 (0.29–0.99)0.51 (0.27–0.97)
  • a OR adjusted for age, age at first birth, history of tubal ligation, parity, presence of irregular menses, and family history of ovarian cancer.

  • b Regular use defined as self-reported use at least once a week for 6 consecutive months.